# VIVOS THERAPEUTICS, INC. (VVOS) · Edgar & Edgarette company card

> Vivos Therapeutics (VVOS) grew revenue 16.0% in FY2025 to $17 million, operating margin -114% against a 1.2% median for surgical & medical instruments & apparatus, equity -5.9% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1716166 · fiscal year ended 2025-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/VVOS) · [JSON](https://www.pops4.com/boards/company/VVOS.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $17M |
| Revenue growth, 1 year | 16.0% |
| Revenue growth per year | 0.8% |
| Operating margin | -114.1% (prior year -74.3%) |
| Net margin | -121.7% |
| Operating cash flow | −$15M |
| Capital spending | $2M |
| Free cash flow | −$18M |
| Cash | $2M |
| Long-term debt | $9M |
| Total assets | $25M |
| Total equity | −$1M |
| Equity ÷ assets | -5.9% |
| Return on equity | — |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: -25.19 (distress zone)
- Piotroski F: 3 of 9 (middling)
- Beneish M: -1.31 (above the −1.78 line)
- Health Harbor boat: Rotting at the dock · four or more warning signs · filed late annual report notice, late quarterly report notice, auditor change in the last 12 months; liabilities exceed assets (often from years of share buybacks, not always distress); operating cash flow was negative; operating loss: a margin of -114.1% in FY2025; revenue is hard to predict: its 80% range is ±40%
- Cash Compass: In between · no clear cash pattern yet

## Edgarette's reading

Exposure: revenue $17.4M (FY2025), total debt $8.8M. Experience: revenue up 16.0% on the year, up 0.8% a year over 4 years; operating margin -114.1%, down from -74.3%. Soundness: equity -5.9% of assets (liabilities exceed assets). Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $12.2M and $28.6M next year (method v4.1: its own 6-year record of growth weighed at 63% against under $50M filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $11.5M to $30.4M. A statistical range, not company guidance. Against peers (60 filers, $50M+ revenue, surgical & medical instruments & apparatus): operating margin -114.1% against a 1.2% median; growth 16.0% against 11.6%.

Range logged 2026-09-25, receipt a8426060936f1ca9, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item NT 10-K Late annual report notice: 1, latest 2026-03-31 ([filing](https://www.sec.gov/Archives/edgar/data/1716166/000149315226014114/0001493152-26-014114-index.htm))
- Item 3.01 Exchange listing notice or transfer: 2, latest 2026-06-08 ([filing](https://www.sec.gov/Archives/edgar/data/1716166/000149315226027641/0001493152-26-027641-index.htm))
- Item NT 10-Q Late quarterly report notice: 2, latest 2026-05-15 ([filing](https://www.sec.gov/Archives/edgar/data/1716166/000149315226023733/0001493152-26-023733-index.htm))
- Item 4.01 Auditor change: 1, latest 2026-10-01 ([filing](https://www.sec.gov/Archives/edgar/data/1716166/000149315226045193/0001493152-26-045193-index.htm))
- Item 5.02 Director or officer change: 2, latest 2026-08-03 ([filing](https://www.sec.gov/Archives/edgar/data/1716166/000149315226035867/0001493152-26-035867-index.htm))

## Recent filings

- DEF 14A · filed 2026-10-29 · [filing](https://www.sec.gov/Archives/edgar/data/1716166/000149315226049258/0001493152-26-049258-index.htm)
- 8-K · filed 2026-10-21 · 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1716166/000149315226047841/0001493152-26-047841-index.htm)
- 8-K · filed 2026-10-19 · 1.01 Entry into a Material Definitive Agreement; 2.01 Completion of Acquisition or Disposition of Assets; 3.02 Unregistered Sales of Equity Securities; 3.03 Material Modifications to Rights of Security Holders; 5.03 Amendments to Articles or Bylaws; Change in Fiscal Year; 7.01 Regulation FD Disclosure; 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1716166/000149315226047601/0001493152-26-047601-index.htm)
- 8-K · filed 2026-10-15 · 1.01 Entry into a Material Definitive Agreement; 7.01 Regulation FD Disclosure; 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1716166/000149315226047158/0001493152-26-047158-index.htm)
- 8-K · filed 2026-10-01 · 4.01 Changes in Registrant's Certifying Accountant; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1716166/000149315226045193/0001493152-26-045193-index.htm)
- 8-K · filed 2026-09-08 · 1.01 Entry into a Material Definitive Agreement; 3.02 Unregistered Sales of Equity Securities; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1716166/000149315226041616/0001493152-26-041616-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001716166.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1716166

## Cite

POPS4, Edgar & Edgarette: VIVOS THERAPEUTICS, INC. (VVOS) company card, from the company's own SEC filings, accessed 2026-11-04, https://www.pops4.com/boards/company/VVOS. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.